Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...
Compass Pathways stated it intends to use the proceeds to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in post-traumatic stress disorder, acceleration of commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results